RB1 + TP53 共突变：EGFR 突变肺癌小细胞转化风险的原始临床证据
类型: 原始研究 / 回顾性队列 发表日期: 2019-06-19 入库日期: 2026-05-21 来源: PubMed / Journal of Thoracic Oncology 标签: EGFR L858R, RB1, TP53, 小细胞转化, NSE, 再活检, 高风险分层
Citation
Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at Risk for Histologic Transformation and Inferior Clinical Outcomes. Journal of Thoracic Oncology. 2019. PMID: 31228622. DOI: 10.1016/j.jtho.2019.06.002
Why it matters for mom
Mom's baseline molecular pathology shows EGFR L858R, TP53 p.G105V, and RB1 frameshift p.P39Sfs*5. This paper is important because it is one of the original clinical datasets connecting concurrent RB1/TP53 alterations in EGFR-mutant lung cancer with higher risk of histologic transformation and poorer outcomes.
This does not prove transformation has happened. It makes transformation a specific item to monitor when there is discordant response, new growth pattern, or neuroendocrine marker movement such as NSE/ProGRP.
Practical takeaways
- Treat RB1 + TP53 as a baseline risk flag for lineage plasticity.
- If progression is suspected, ask whether tissue biopsy is feasible, not only blood NGS.
- If NSE rises again or imaging pattern changes rapidly, ask specifically about small-cell/neuroendocrine transformation workup.
- Pathology confirmation matters because treatment usually changes if transformation is confirmed.
Questions for doctors
- Does the current imaging/marker pattern warrant tissue biopsy of the progressing lesion?
- If biopsy is done, will pathology include neuroendocrine markers such as synaptophysin, chromogranin, CD56, Ki-67, and RB1/p53 IHC?
- Should blood NGS and tissue NGS both be considered, given possible spatial heterogeneity?